StockData
Immunovant, Inc. logo

Immunovant, Inc. (IMVT) stock

IMVTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/30
$33.17−0.04 (-0.12%)

Close on Nov 18, 2026Market cap $6.85BP/E –Yield –

Immunovant shares outstanding

Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.

Immunovant's shares outstanding was 206M at Jun 30, 2026. For fiscal 2026 it was 182M, up 20.4% from the year before. The highest annual figure on record is 182M in fiscal 2026.

Annual shares outstanding

PeriodPeriod endValueChange
FY2026Mar 31, 2026182M+20.4%
FY2025Mar 31, 2025152M+9.8%
FY2024Mar 31, 2024138M+12.2%
FY2023Mar 31, 2023123M+12.2%
FY2022Mar 31, 2022110M+25.0%
FY2021Mar 31, 202188M+103.1%
FY2020Mar 31, 202043M+94.8%
FY2019Mar 31, 201922M–

Quarterly shares outstanding

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2027CQ2 2026Jun 30, 2026206M+20.3%
Q4 FY2026CQ1 2026Mar 31, 2026203M+22.1%
Q3 FY2026CQ4 2025Dec 31, 2025182M+23.5%
Q2 FY2026CQ3 2025Sep 30, 2025174M+18.6%
Q1 FY2026CQ2 2025Jun 30, 2025171M+17.0%
Q4 FY2025CQ1 2025Mar 31, 2025167M+14.4%
Q3 FY2025CQ4 2024Dec 31, 2024147M+1.7%
Q2 FY2025CQ3 2024Sep 30, 2024146M+11.7%
Q1 FY2025CQ2 2024Jun 30, 2024146M+11.9%
Q4 FY2024CQ1 2024Mar 31, 2024146M+11.8%
Q3 FY2024CQ4 2023Dec 31, 2023145M+12.4%
Q2 FY2024CQ3 2023Sep 30, 2023131M+12.5%
Q1 FY2024CQ2 2023Jun 30, 2023131M+12.0%
Q4 FY2023CQ1 2023Mar 31, 2023130M+12.0%
Q3 FY2023CQ4 2022Dec 31, 2022129M+11.8%
Q2 FY2023CQ3 2022Sep 30, 2022117M+6.9%
Q1 FY2023CQ2 2022Jun 30, 2022117M+19.0%
Q4 FY2022CQ1 2022Mar 31, 2022116M+19.0%
Q3 FY2022CQ4 2021Dec 31, 2021115M+17.5%
Q2 FY2022CQ3 2021Sep 30, 2021109M+29.3%
Q1 FY2022CQ2 2021Jun 30, 202198M+38.3%
Q4 FY2021CQ1 2021Mar 31, 202198M+71.5%
Q3 FY2021CQ4 2020Dec 31, 202098M+153.7%
Q2 FY2021CQ3 2020Sep 30, 202084M+912.2%
Q1 FY2021CQ2 2020Jun 30, 202071M+92.8%
Q4 FY2020CQ1 2020Mar 31, 202057M–
Q1 FY2020CQ2 2019Jun 30, 201939M–
Q4 FY2019CQ1 2019Mar 31, 20198M–
Q3 FY2019CQ4 2018Dec 31, 201837M–

More Immunovant figures

See a number that looks wrong?